Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
about
Administration of low molecular weight and unfractionated heparin during percutaneous coronary interventionOral direct thrombin inhibition: a double-edged sword?Coronary thrombus in patients undergoing primary PCI for STEMI: Prognostic significance and managementBleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.Effect of Heparin Administration during Coronary Angiography on Vascular or Peripheral Complications: A Single-Blind Randomized Controlled Clinical Trial.Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.Pharmaco-mechanic antithrombotic strategies to reperfusion of the infarct-related artery in patients with ST-elevation acute myocardial infarctionsAntiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013.Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection.Recent advances in antithrombotic treatment for acute coronary syndromes.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of EAnticoagulation in coronary intervention.The toxicology of heparin reversal with protamine: past, present and future.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Association of Interventional Cardiology (SICI-GISE) and Italian Society of Cardiac Surgery (SICCH): clinical approach to pClinical experience of anti-Xa monitoring in critically ill dogs receiving dalteparin.Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets.Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial.Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention.Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC.High-dose enoxaparin in the treatment of abdominal angiostrongyliasis in Swiss mice.CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018.Optimal treatment of patients with NSTE-ACS in the Dutch health care system.Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.The Efficacy and Safety of Enoxaparin: A Meta-analysisPrimary versus secondary source of data in observational studies and heterogeneity in meta-analyses of drug effects: a survey of major medical journals
P2860
Q26748752-08D62698-8B0D-40F7-B534-563AA46C7475Q26780154-FC050E67-F862-48D0-8C66-984857D8EB40Q26830317-3B646A72-D1EF-47B7-91E4-A33CEFA1DE89Q34415964-4BAF3EA0-AEC4-44FF-91C2-EE57BCE6A076Q37338868-CC927B46-4C4D-4CDD-A692-5F5C23379E0BQ38037672-5ECE5C8C-C033-40D8-ADCD-B7A0C24467F7Q38081377-0A96CA0A-A032-48E7-A57F-A7658C33B1F6Q38106501-A67716F1-CD45-4201-8EE7-862BCBC77FACQ38199360-89DA67F5-476B-4E19-849F-B61CF63DA02FQ38216600-60D913A1-EA24-4F8A-8013-7328E0BF08BAQ38656364-B5B680BD-0BD4-4D75-A4DC-BCBC40C27B14Q38762278-A9ACDA26-4C3E-45C2-8514-E574EDCAE826Q38844058-3D19E7E9-C821-4B27-8DC2-1DEC33F423B0Q39147735-782BE098-3088-46FD-9F2E-CD297602C3ABQ41082977-B279BA4B-A1C1-4B3E-8BAC-76E26203D640Q44082992-737E2535-E98A-4DF8-8DC7-BA5592C6C48AQ48512017-A1D5AC50-82B6-4853-90D2-883E0217867CQ50237653-DBADDA05-8A26-4D9D-B594-BF574864A9D6Q51065519-C292A676-62F3-470A-8087-95F911D8AD22Q52342075-CA4C7B09-DCFE-4CD2-9898-504604607C3AQ52862832-2AB93D76-3CFB-44E2-8D89-BE1832AA6A62Q54337564-BFE78161-3367-48D4-9FAC-BE4D18B1199DQ55154820-C6FCAB0E-AEF8-45CE-8049-A606B2A024BFQ55204798-F55D42F1-1AB1-4573-890C-300E3A6FC53EQ55484350-DF1ADD44-B14E-4DBA-8632-E118EA119122Q58757769-2C821D3A-1477-4892-B49F-27ABF4C58E25Q59128777-876D3692-D2C0-4D02-87F8-0C65008255AA
P2860
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@ast
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@en
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@nl
type
label
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@ast
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@en
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@nl
prefLabel
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@ast
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@en
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P921
P356
P1433
P1476
Efficacy and safety of enoxapa ...... matic review and meta-analysis
@en
P2093
Barthélémy O
Goldstein P
Pollack C Jr
P2860
P356
10.1136/BMJ.E553
P407
P5008
P577
2012-02-03T00:00:00Z